ALX Oncology HoldingsALXO

ALX Oncology Holdings

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials.

CEO
Mr. Jaume Pons, PhD
-0.10000000149011612 / 50 reviews
-10% recommend to a friend

$340M

Market Cap • 02/06/2023

2020

(3 years ago)
Founded

2020

(3 years ago)
IPO

South San Francisco

Headquarters • California

58

Employees 2022

Valuation

Valuation Indicators
YearEquityRevenueEBITDAFin. Res.Net Inc.Net Mar.ROECashDebtN.D. / EBITDAOCFCAPEXFCFFreeDiv.
03/23 TTM2400-1326-129LL22810L-96-210-980

The values above are represented in USD and the scale is in millions—10.000 is the equivalent of 10 billions. L inside the table means Loss.